Efficacy and safety of intensive triglyceride-lowering therapy on reducing recurrence of hypertriglyceridemia-associated pancreatitis (REDUCE): protocol for a multicentre, randomised controlled trial.

1 HTG has emerged as the third most common cause, accounting for approximately 4.7% of all cases globally with an increasing trend. 2 3 In China, HTG has escalated to become the second leading cause of AP with an increasing trend, now accounting for over 25% of cases. 4 , 6 Recurrence of HTG-associated acute pancreatitis (HTG-AP) is frequent. 7 Recurrent AP (RAP) contributes significantly to the overall disease burden by neces

also in 63,971 other papers